Recommendations for NSAIDs in Patients with Cardiovascular Disease

Risk Assessment and Stepped-Care Approach

The American Heart Association recommends that in patients with cardiovascular disease, NSAIDs should be avoided whenever possible due to their increased risk of serious cardiovascular events, and if absolutely necessary, naproxen at the lowest effective dose for the shortest duration is preferred 1, 2
The risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, appears to be proportional to COX-2 selectivity and the underlying cardiovascular risk of the patient 2
Naproxen has shown the most favorable cardiovascular risk profile among NSAIDs, with a relative risk of 0.92 for vascular events 3
Diclofenac has demonstrated significantly higher cardiovascular risk, with a relative risk of 1.63 for vascular events 3
Ibuprofen shows intermediate risk, with a relative risk of 1.51 for vascular events 3
COX-2 selective inhibitors consistently show increased cardiovascular risk compared to placebo 4

The American College of Cardiology recommends beginning with non-pharmacological approaches for pain management whenever possible, and for pharmacological therapy, starting with acetaminophen, nonacetylated salicylates, tramadol, or small doses of narcotics 1, 2
If first-line treatments are insufficient, consider nonselective NSAIDs with lower cardiovascular risk, preferably naproxen, at the lowest effective dose for the shortest possible duration 1, 2
Add low-dose aspirin for patients at high cardiovascular risk, and consider adding a proton pump inhibitor to reduce gastrointestinal bleeding risk, especially in patients taking both NSAIDs and aspirin 2

Observational studies show that NSAID use in post-MI patients significantly increases risk of reinfarction, cardiovascular death, and all-cause mortality 2
In a Danish registry study of first-time MI patients, mortality hazard ratios were 2.80 for rofecoxib, 2.57 for celecoxib, 1.50 for ibuprofen, and 2.40 for diclofenac 2
Regularly assess for signs of fluid retention, edema, worsening heart failure, and renal function deterioration, and consider dose reduction or discontinuation if adverse effects occur 2

Assuming that all NSAIDs carry equal cardiovascular risk is incorrect, with diclofenac and COX-2 inhibitors showing consistently higher risk 3, 2
Failing to consider alternative pain management strategies before resorting to NSAIDs is a common pitfall, and the American Heart Association recommends prioritizing safer alternatives whenever possible 2

The American College of Cardiology and American Heart Association recommend against NSAID use in patients with established cardiovascular disease, including recent stroke, because of a markedly increased risk of recurrent thrombotic events and mortality. Class I, Level A recommendation. 5
The 2011 ACC/AHA guidelines provide no specific recommendation for NSAIDs in extracranial carotid or vertebral artery disease, citing limited evidence and noting that vascular risk is more evident for myocardial infarction than for stroke. Evidence: limited/neutral. 6
The 2018 CHEST guidelines identify NSAIDs as modifiable bleeding‑risk factors and advise avoidance in patients receiving anticoagulation therapy. Class I, Level B recommendation. 7

Cardiovascular risk from NSAIDs increases with greater COX‑2 selectivity and with higher baseline vascular risk in the patient. Observational data supporting a dose‑ and selectivity‑related effect. 8

First‑line therapy: Scheduled acetaminophen 650–1000 mg every 6 hours; maximum 3 g/day for adults ≥ 60 years and 4 g/day for younger adults. Guideline recommendation for safe pain/fever control after stroke. 8
Second‑line therapy (if acetaminophen insufficient): Tramadol 50–100 mg every 4–6 hours as needed (max 400 mg/day) or low‑dose non‑acetylated salicylates/narcotics, per ACC guidance. Guideline recommendation for step‑up analgesia. 8

Combined NSAID + antiplatelet therapy increases gastrointestinal bleeding risk 3‑ to 6‑fold. Observational cohort evidence. 9
NSAIDs can precipitate volume‑dependent renal failure, especially in patients concurrently taking ACE inhibitors or other cardiovascular medications commonly prescribed post‑stroke. Observational data. 9